Apollon Formularies plc Directors' Dealing
September 13 2022 - 02:02AM
UK Regulatory (RNS & others)
TIDMAPOL
RNS Number : 1849Z
Apollon Formularies plc
13 September 2022
13 September 2022
Apollon Formularies Plc
("Apollon" or the "Company")
Directors' Dealing
Apollon Formularies plc (AQSE: APOL), a UK based international
pharmaceutical company trading on the Aquis Stock Exchange,
announces that it has been notified on 13(th) of September 2022,
that Roderick ("Rod") Claude McIllree, Non-Executive Director, has
transferred 10,000,000 Ordinary Shares for nil consideration to
Stene Jacobs, Chief Operating Officer, on 13(th) of September
2022.
Following the transfer, Rod McIllree is interested in
207,485,940 Ordinary Shares representing approximately 26.9% of the
issued share capital of the Company.
Following the transfer, Stene Jacobs is interested in 11,382,306
Ordinary Shares representing approximately 1.48% of the issued
share capital of the Company.
The Directors of the Company accept responsibility for the
contents of this announcement.
ENDS
For additional information, please visit www.apollon.org.uk or
contact:
Apollon Formularies
Tel: +44 771 198 0221
Stene Jacobs stene@apollon.org.uk
Peterhouse Capital Limited (Corporate Adviser)
Tel: +44 207 220 9795
Guy Miller gm@peterhousecapital.com
BlytheRay (Financial PR/IR-London)
Tel: +44 207 138 3204
Tim Blythe/Megan Ray apollon@blytheray.com
About Apollon and Apollon Jamaica
Apollon Formularies plc is an international medical cannabis
company headquartered in the United Kingdom. Apollon Formularies
Jamaica Limited is a pharmaceutical company incorporated and
operating in the Commonwealth of Jamaica. Apollon Jamaica is
licensed by the Jamaican government's Cannabis Licensing Authority
(CLA) to cultivate, perform research and development, process, and
sell medical cannabis therapeutic products that include legal
medical cannabis to treat various illnesses under medical
supervision. Apollon and Apollon Jamaica are parties to a
Commitment Agreement whereby Apollon is entitled to 95% of Apollon
Jamaica's Net Profits, and per a Stock Pledge Agreement that
includes Stephen D. Barnhill, M.D., Apollon is to be assigned the
entire 49% equity interest of Apollon Jamaica held by Dr. Barnhill,
which is the maximum interest in a medical cannabis company allowed
to be held by a non-Jamaican, upon the CLA approving the
assignment.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY
ASSOCIATED WITH THEM
1. Details of the person discharging managerial responsibilities/person closely associated
a) Name: Roderick ("Rod") Claude McIllree
2. Reason for the notification
a) Position/status: Non-Executive Director
b) Initial notification/Amendment: Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
a) Name: Apollon Formularies plc
b) LEI: 21300ZW9OCVM8OIEO02
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
a) Description of the financial instrument, type of instrument: Ordinary shares of no par value
Identification code: IM00BJ0LRD77
b) Nature of the transaction: Transfer to another PDMR for Nil Consideration
c) Price(s) and volume(s): Issue of shares Price(s) Volume(s)
Nil 10,000,000
Issue of warrants Price(s) Volume(s)
N/A N/A
d) Aggregated information: Single transaction as in 4 c) above
Aggregated volume: Issue of shares Price(s) Volume(s)
Price:
Issue of warrants Price(s) Volume(s)
N/A N/A
e) Date of the transaction: 13 September 2022
f) Place of the transaction: AQSE Growth Market
1. Details of the person discharging managerial responsibilities/person closely associated
a) Name: Stene Jacobs
2. Reason for the notification
a) Position/status: Chief Operating Officer
b) Initial notification/Amendment: Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
a) Name: Apollon Formularies plc
b) LEI: 21300ZW9OCVM8OIEO02
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
a) Description of the financial instrument, type of instrument: Ordinary shares of no par value
Identification code: IM00BJ0LRD77
b) Nature of the transaction: Receipt from another PDMR for Nil Consideration
c) Price(s) and volume(s): Issue of shares Price(s) Volume(s)
Nil 10,000,000
Issue of warrants Price(s) Volume(s)
N/A N/A
d) Aggregated information: Single transaction as in 4 c) above
Aggregated volume: Issue of shares Price(s) Volume(s)
Price:
Issue of warrants Price(s) Volume(s)
N/A N/A
e) Date of the transaction: 13 September 2022
f) Place of the transaction: AQSE Growth Market
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NEXEAENAFEXAEAA
(END) Dow Jones Newswires
September 13, 2022 02:02 ET (06:02 GMT)
Apollon Formularies (AQSE:APOL)
Historical Stock Chart
From Feb 2023 to Mar 2023
Apollon Formularies (AQSE:APOL)
Historical Stock Chart
From Mar 2022 to Mar 2023
